Increased concentrations of urinary neopterin, an indicator of systemic immune activation, have been reported in patients with cancer, including epithelial ovarian carcinoma (EOC). We have assessed urinary neopterin before the treatment and then daily during the therapy with paclitaxel/platinum combination in 5 EOC patients. A correlation was observed between the clinical course and serial urinary neopterin concentrations. We conclude that the determination of serial urinary neopterin concentrations may be useful for monitoring of EOC patients during chemotherapy.
Introduction
Urinary and serum concentrations of neopterin, an indicator of systemic immune activation, are increased in patients with advanced tumors, including epithelial ovarian carcinoma (EOC) (1) . In patients with EOC, increased neopterin is an independent prognostic factor associated with inferior survival (2) (3) (4) . The prognosis of patients with EOC has improved markedly over the last decades, and the combination of platinum derivatives (cisplatin or carboplatin) with paclitaxel is currently the standard front line regimen for patients with advanced EOC (5, 6) .
We have assessed urinary neopterin before the treatment and then daily during the therapy with paclitaxel/platinum combination in 5 EOC patients. We have observed a correlation between the clinical course and serial urinary neopterin concentrations that is illustrated by the case descriptions outlined below.
Method
Urine sample was collected immediately before the start of therapy (day 0), patients were issued collection vessels for first morning urine specimens and advised to keep the samples refrigerated and protected from daylight. Specimens were collected at scheduled visits and stored at -20 o C until analysis. After centrifugation (5 minutes, 1300 g) and diluting 100 µl of urine specimens with 1.0 ml of mobile phase containing 2 g of disodium-EDTA per liter, samples were injected onto a column, and neopterin was determined using high performance liquid chromatography systems Prominence LC20 (Shimadzu, Kyoto, Japan) as described (7) . Neopterin was identified by its native fluorescence (353 nm excitation, 438 nm emission) and quantified by external standard method. Creatinine was determined by Jaffé reaction after dilution of the sample 1:50 on a Hitachi 716 analyser (Tokyo, Japan) using a commercial kit (Boehringer, Mannheim, Germany) according the manufacturer's instructions, and neopterin concentrations were expressed as neopterin/creatinine ratio (µmol/mol creatinine). Serum CA125 was determined by immunoradiometric assay using a commercial kit (Immunotech, Marseille, France) according the manufacturer's instructions.
Results
Baseline urinary neopterin concentrations were above the normal range in most (4 out of 5) patients studied. Subsequent course of values obtained in daily neopterin measurements differed in individual patients and reflected the clinical course.
Patient 1 was a 64-year-old woman with history of bilateral breast carcinoma and recurrent EOC. She presented with second recurrence of EOC that manifested as ascites. Tumor cells were identified during cytological examination of the ascites. Because of interval from the last paclitaxel/platinum therapy of more than 6 months, the patient was treated with the combination of paclitaxel (Taxol, Bristol-Myers Squibb, Sermoneta, Italy; 175 mg/m 2 ) and carboplatin (Cycloplatin, PlivaLachema, Brno, Czech Republic; area under the curve 6) every 3 weeks that resulted in complete disappearance of ascites and normalization of serum CA125. Urinary neopterin was measured daily during the initial two cycles of therapy. Marked peaks of urinary neopterin were observed in the first week after administration of each dose of chemotherapy, but initially increased urinary neopterin concentrations gradually declined to normal range ( Figure 1) .
Patient 2 was a 52-year-old woman with recurrent EOC and breast carcinoma. EOC recurrent after first line paclitaxel/carboplatin chemotherapy progressed on therapy with docetaxel and cisplatin, gemcitabine and cisplatin, and topotecan. As a treatment of last resort, the patient was offered therapy with the combination of cetuximab (Erbitux, Merck, Darmstadt, Germany; 400 mg/m 2 loading dose, then 250 mg/m 2 weekly), paclitaxel (Taxol; 90 mg/m 2 weekly), oxaliplatin (Eloxatin, Sanofi-Aventis, Quetigny, France; 50 mg/m 2 weekly), and continuous 5-fluorouracil (Ebewe, Unterach, Austria; 160 mg/m 2 /day). The therapy was initially well tolerated, but during the second week of therapy the patient reported nausea and vomiting that coincided with a marked peak of urinary neopterin concentrations. The administration of continuous 5-fluorouracil infusion was interrupted on day 11 and administration of paclitaxel and oxaliplatin was suspended after 3 weekly doses (on days 0, 7 and 14). The general condition of the patient declined further during subsequent administration of cetuximab in monotherapy on days 21, 28 and 35. The course of urinary neopterin concentrations was characterized by marked fluctuation and a gradual increase during the observation period. The rise of urinary neopterin reflected the deterioration of the condition of the patient who was complaining of weakness, nausea and, in the last week of observation, pain associated with the tumor growth. The patient died 13 days after the last measurement ( Figure 2) .
Patient 3 was an 81-year-old woman who came to the hospital with clinical signs of intestinal obstruction. Peritoneal carcinomatosis of ovarian origin was discovered during exploratory laparotomy. Surgical palliation of intestinal obstruction was not possible, and as a therapy of last resort the patient was treated with the combination of paclitaxel (Taxol; 90 mg/m 2 ) and carboplatin (Cycloplatin; area under the curve 2) every week. Only two doses of chemotherapy were administered (on days 0 and 7). The administration of therapy was complicated by diarrhea (more than 10 bowel movements/days) that started on day 5. The diarrhea was first considered to be the result of reestablishment of bowel transit after previous obstruction, and second dose of therapy was administered. The diarrhea continued and was accompanied by a rise of urinary neopterin. Despite supportive therapy, the general status of the patient did not improve, and she died less than 24 hours after the last measurement. A gradual rise in urinary neopterin concentrations was observed until the death of the patient ( Figure 3 ).
Patient 4 was a 69-year-old woman with history of breast carcinoma and second recurrence of EOC. She was re-treated with the combination of paclitaxel (Taxol; 175 mg/m 2 ) and carboplatin (Cycloplatin; area under the curve 6). On day 5 the patient complained about fever and weakness, and therapy with oral ofloxacin (Ofloxin, Zentiva, Praha, Czech Republic) was started. Two days later she came for a scheduled visit complaining about the deterioration of general status, anuria and anorexia. A marked rise of serum creatinine was detected (from 90 to 382 µmol/l). The patient was admitted, and her condition transiently improved after infusion therapy. However, on day 9 sepsis with hypotension and multiple organ failure was evident, and the patient died despite intensive therapy on day 12. A marked increase in urinary neopterin was observed after the administration of therapy, preceding the manifestation of the fatal complication ( Figure 4) .
Patient 5 was a 48-year-old woman with second recurrence of EOC that manifested as ascites that was positive for tumor cells on cytology. Because of interval from the last paclitaxel/platinum therapy of more than 6 months, the patient was treated with the combination of paclitaxel (Taxol; 175 mg/m 2 ) and carboplatin (Cycloplatin; area under the curve 6) every 3 weeks that resulted in regression of ascites. The administration of the second dose had to be postponed because of prolonged neutropenia until after the last measurement. Filgrastim (Neupogen, Amgen, Thousand Oaks, CA, USA; 480 µg subcutaneously) was administered on days 10 -12, resulting in a rise of urinary neopterin concentrations. Besides this peak, fluctuations of neopterin concentrations with peaks of few days' duration were observed during the first cycle ( Figure 5 ). 2 ) and carboplatin (area under the curve 6) every 3 weeks. Urinary neopterin was measured daily during the initial two cycles of therapy. Marked peaks of urinary neopterin were observed in the first week after administration of each dose of chemotherapy on days 0 and 22, but initially increased urinary neopterin concentrations gradually declined to normal range (from 333 to 156 µmol/mol creatinine). Serum CA125 concentrations declined during the same period from 2323 to 104 U/ml, and decreased to normal range during subsequent cycles of therapy. The urinary neopterin concentration of 213 µmol/mol creatinine defined as upper limit of normal in an earlier study is indicated by a line (4). The therapy was tolerated well during the first weeks, but during the second week of therapy the patient reported nausea and vomiting that coincided with a marked peak of urinary neopterin concentrations. The administration of continuous 5-fluorouracil was interrupted on day 11 and administration of paclitaxel and oxaliplatin was suspended after 3 weekly doses (on days 0, 7 and 14). The general condition of the patient declined further during subsequent administration of cetuximab in monotherapy on days 21, 28 and 35. The course of urinary neopterin concentrations was characterized by marked fluctuation and a gradual increase during the observation period. The rise of urinary neopterin reflected the deterioration of the condition of the patient who was complaining of weakness, nausea and, in the last week of observation, pain associated with the tumor growth. The patient died 13 days after the last measurement. Serum CA125 was markedly increased (20 000 U/ml and above) throughout the course of therapy. The upper limit of normal urinary neopterin concentrations is indicated by dashed line.
Discussion
Differences in the course of serial urinary neopterin concentrations in the present study reflected differences in the disease course during chemotherapy with paclitaxel/platinum combination. EOC is currently the 2 ) and carboplatin (area under the curve 6). On day 5 the patient complained about fever and weakness, and therapy with oral ofloxacin was started. Two days later she came for a schedule visit complaining about the deterioration of general status, anuria and anorexia. A marked rise of serum creatinine was detected (from 90 to 382 µmol/l). The patient was admitted and transiently improved after infusion therapy. However, on day 9 sepsis with hypotension and multiple organ failure was evident, and the patient died despite intensive therapy on day 12. A marked increase in urinary neopterin was observed after the administration of therapy, preceding the manifestation of the fatal complication. The upper limit of normal urinary neopterin concentrations is indicated by dashed line. neopterin(µ µmol/mol creatinine) Figure 3 . An 81-year-old woman with peritoneal carcinomatosis of ovarian origin that manifested as intestinal obstruction was treated with the combination of paclitaxel (90 mg/m 2 ) and carboplatin (area under the curve 2) every week. Two doses of chemotherapy were administered on days 0 and 7. The administration of therapy was complicated by diarrhea (more than 10 bowel movements/days) that started on day 5. The diarrhea was first considered to be the result of re-establishment of bowel transit after previous obstruction, and second dose of therapy was administered, but the diarrhea continued and was accompanied by a rise of urinary neopterin. Despite supportive therapy, the general status of the patient did not improve, and she died less than 24 hours after the last measurement. A gradual rise in urinary neopterin concentrations was observed until the death of the patient. Serum CA125 decreased during the observation from 1158 to 800 U/ml. The upper limit of normal urinary neopterin concentrations is indicated by dashed line. leading cause of mortality for gynecological cancer (8) . The high mortality rate of EOC reflects the difficulty in early diagnosis, and despite aggressive surgery and chemotherapy, most patients with advanced disease will ultimately relapse and die. On the other hand, the survival of patients with EOC has improved substantially over the recent decades. Combination of platinum derivatives (cisplatin or carboplatin) with paclitaxel currently represents the standard front line regimen for patients with advanced disease after demonstration of superior survival in randomized clinical trials (5, 6) .
Neopterin is an unconjugated pteridine produced from guanosine triphosphate (GTP). GTP is converted to 7,8-dihydroneopterin triphosphate (which subsequently undergoes autooxidation to neopterin) by the enzyme GTP cyclohydrolase I, in a reaction that is the rate-limiting step in the pathway leading to the formation of tetrahydrobiopterin (9) . The activity of GTP cyclohydrolase I is induced by interferon-γ (IFN-γ) (10), a cytokine produced by T-lymphocytes and natural killer cells. Human macrophages possess significant GTP cyclohydrolase I activity when stimulated by IFN-γ, while the activities of other enzymes of this pathway are low (11), leading to the accumulation of neopterin. Thus, measurement of neopterin concentrations may be used to assess macrophage activation and systemic immune activation. In earlier studies of serial urinary neopterin measurements in EOC, it has been reported that neopterin concentrations decrease after successful therapy and increase during disease progression. Increased neopterin concentrations were also observed before death (3, (12) (13) (14) . However, the intervals between measurements in these studies were longer (several days or several weeks). Results of daily measurements of urinary neopterin during therapy have been reported in a single patient with nonHodgkin's lymphoma (15) . In this report, marked fluctuations of daily neopterin concentrations with a trend of a decrease during therapy were observed. The fluctuations of daily neopterin measurements in the present report were less pronounced. This difference may reflect the difference between biology of nonHodgkin's lymphoma, a neoplasm originating from the cells of the immune system, and EOC, a tumor that involves cells of the immune system only through secondary mechanisms. The daily monitoring of urinary neopterin concentrations used in the present study allowed an insight into the dynamics of interactions between the host and neoplasm during chemotherapy. The course and the outcome of the therapy differed in the patients presented here, therefore, a formal statistical analysis of the sequential data would be difficult and could even be misleading. In general, neopterin concentrations reflected the disease course, and progressive disease or complications of therapy were accompanied by a marked increase in urinary neopterin. A marked rise of urinary neopterin was associated with imminent death. In one patient, increase of urinary neopterin of an order of magnitude Figure 5 . A 48-year-old woman with second recurrence of EOC was treated with the combination of paclitaxel (175 mg/m 2 ) and carboplatin (area under the curve 6) every 3 weeks that resulted in regression of ascites. The initial urinary neopterin concentration was within the normal range. The administration of the second dose had to be postponed because of prolonged neutropenia until after the last measurement. Filgrastim (480 µg subcutaneously) was administered on days 10 -12, resulting in a rise of urinary neopterin concentrations. Besides this peak, fluctuations of neopterin concentrations with peaks of few days' duration were observed during the first cycle. Serum CA125 was only mildly increased (128 U/ml) and decreased during the treatment (69 U/ml). The upper limit of normal urinary neopterin concentrations is indicated by dashed line. preceded a fatal sepsis that was clinically evident only days later.
An increase of neopterin production has been documented after systemic administration of different cytokines (1) as well as in breast cancer patients treated with the combination of paclitaxel and doxorubicin (16) . Moreover, both paclitaxel and cisplatin have been shown to activate macrophages in vitro (17, 18) . In the present study we observed an increase of urinary neopterin concentrations after paclitaxel/platinum administration in some patients. In other patients, a distinct peak associated with administration of therapy was absent. Baseline urinary neopterin was increased above the normal range in all but one patient studied. Reduction of the tumor burden may result in lower neopterin as has been reported earlier (14) , and this decrease might compromise any increase induced by activation of monocytes/macrophages by paclitaxel or platinum. The absence of a pronounced rise of urinary neopterin concentration could also indicate a paralysis of the immune response in patients with advanced cancer, or a rise resulting from macrophage activation induced by paclitaxel or platinum could be masked by increased neopterin concentrations caused by intercurrent conditions, e.g. sepsis.
An important advantage of utilization of neopterin for monitoring of systemic immune activation is that neopterin can be measured in urine. Consequently, samples may be collected repeatedly without the need for venepuncture, increasing the comfort for the patient. In addition, when refrigerated, neopterin is stable in urine for two weeks (19) , and neopterin measurement can be used for outpatient monitoring without the need for repeated office visit. Determination of urinary neopterin in samples collected between the office visits allows objective assessment of any episode that is reported by the patient. Not unlike a flight recorder, the data from serial neopterin measurements could be useful in safety monitoring, and analysis of serial neopterin measurements could become an important tool in the monitoring of patients receiving anticancer drugs in prospective clinical trials. A retrospective analysis of daily neopterin concentrations may provide valuable corroboration of anamnestic data. In hospitalized patients, daily neopterin measurements could alert the physician to complications of therapy. Monitoring of urinary neopterin concentrations has already been proven useful in other clinical situation, e.g. in early detection of transplant rejection (9) . Moreover, increased urinary neopterin may be associated with higher risk of the toxicity of chemotherapy (4, 20) . This association may be explained by the alterations of the metabolism of cytotoxic drugs that accompany systemic inflammatory response (21) , and in patients with increased urinary neopterin concentration closer clinical monitoring of the patients may be warranted.
In conclusion, determination of serial urinary neopterin concentrations may be used for monitoring of EOC patients during paclitaxel/platinum chemotherapy and, possibly, other regimens of chemotherapy.
